Short and Sweet - True InfoFirst:
I don't know rickydee.... But I don't think that he is a Pumper, I own MDG shares and this baby will take off soon. From .33 to .63 (from 23 - 27 July) ... 4 DAYS !!!.
With the following latest news, below and more news in the shadow.... This will just keep going up period.
---------------------------------------------------------------------------------------------------------------------
Second:
Here are my Tips... Free of charges...After all we are all in this boat together... Right !!!
YOU MUST LOOK at
INO-A (US$)
It is swine flu related and their stock just went up TODAY (1 Day) by
+329.73% on 32,105,611 - Just Awesome.
Beside NVAX, You also have to look at MDG, GAP, SSS and INO-A..... Great stocks to own.... BUT please do your own DD before investing as you all know..... nothing is ever Garanteed.
However, I urge you to take a look at them for your own education, research etc.
Good luck to all and lets all make Lots of $$$$$.
Thanks
-----------------------------------------------------------------------------------------------------------------------
Medicago and Genopole(R) Sign Agreement for Influenza Vaccine Production in France
QUEBEC CITY, QUEBEC--(Marketwire - July 21, 2009) - Medicago Inc. (TSXVENTURE:MDG), a biotechnology company focused on developing highlyeffective and affordable vaccines based on proprietary manufacturingtechnologies and Virus-Like Particles (VLP), and Genopole(R) biopark(Evry, France), today announced that they have signed a partnershipagreement with a plan to build a commercial facility to manufacturepandemic and seasonal influenza vaccines in France. Medicago andGenopole(R) believe that this facility could complement France'sexisting domestic influenza vaccine production infrastructure byoffering surge capacity of influenza vaccines before the first wave ofa pandemic strikes. This agreement builds on the feasibility studyannounced in July 2008 which was successfully completed this year toevaluate the economic and technological viability of a novel vaccineproduction facility in France.
Genopole(R) and Medicago will work together to establish acommercial-scale facility based on Medicago's Proficia(TM) plant-basedmanufacturing technology and VLP vaccine technology on Genopole(R)'ssite in Evry, France. The new facility would initially produce pandemicand seasonal influenza vaccines, and in the long-term could be used fora broad range of vaccines and other biodefense related products.Construction of the facility is conditional upon Medicago's successfulcompletion of a Phase I clinical trial with its H5N1 pandemic influenzavaccine and a reasonable level of commitment by the French authoritiesto support this novel technology.
"We are proud to be working with Genopole to contribute towardsthe strengthening of France's health infrastructure," said AndySheldon, President and CEO of Medicago. "This agreement is in line withour strategy to export our rapid and cost-effective solution for themanufacturing of influenza vaccines to enable countries worldwide toproduce their own vaccines, within their own borders."
"We are delighted to be working with Medicago and theirinnovative non-transgenic, plant-based manufacturing technology whichhas great promise for the development of vaccines," said PierreTambourin, Director of Genopole. "This new facility will support ourbiopark's leadership in innovation and bioproduction by offering uniquemanufacturing capabilities to France and Europe."